

## Minutes of the IMpACT meeting at Sanibel Island, Florida, December 6th 2008

**Present:** Bru Cormand, Toni Ramos, Jan Haavik, Andreas Reif, Jan Buitelaar, Phil Asherson, Steve Faraone, Alejandro Arias Vasquez, Martine Hoogman, Anne Halmøy, [as guests: Claiton Bau, Maria Acostas], Barbara Franke (minutes)

### Agenda:

1. Update on current projects
2. Authorship issues in IMpACT: how many authors for each site to put on a paper
3. Database of all patients (phenotypes and/or genotypes): do or don't?
4. Possibilities for funding: where and how
5. Logo for IMpACT
6. IMPACT, IMpACT, impACT

### 1. Update on current projects

#### *Manuscripts (in preparation)*

- DAT1 meta-analysis: paper was rejected by Molecular Psychiatry. It will be resubmitted by Barbara as soon as possible to Biological Psychiatry, with a cover letter referring to the earlier submission of the Dutch-only data.
- Laterality paper, Spain: paper containing data on part of the IMpACT sample (discovery sample Spain, replication samples Germany and Norway) has been submitted to Molecular Psychiatry
- BDNF meta-analysis, Spain: draft is nearly ready to be sent to IMpACT co-authors. It will be submitted to Am. J. Med. Genet. Part B, Neuropsychiatric Genetics.
- Serotonin transporter, TPH1, TPH2 meta-analyses, Norway: These might either be one or two papers. The draft for the 5-HTT will be sent to IMpACT co-authors before Christmas. Additional analyses will include those of symptoms of impulsivity and already published data on adult ADHD will be included.

#### *Projects running*

- NOS1 genotyping, Germany: Norway and Spain are asked to send the phenotyping information to Germany for this paper.
- DRD4 haplotype genotyping, Spain: The VNTR in exon 3 and the 120 bp insertion/deletion in the promoter are analyzed, the 120 bp ins/del is being genotyped in the German sample. Phil also has included his samples in IMpACT now, and has genotyped the exon 3 VNTR. The 120 bp ins/del can be genotyped in Spain and the data can be included in the paper.

### 2. Authorship issues in IMpACT

- As discussed earlier, there will be two different kind of situations regarding publications, one in which a meta-analysis is performed on (existing) data from all partners, another in which a centre proposes a project and wishes to use the samples of the other partners for replication or to increase sample size.
- In meta-analysis papers, we have earlier decided that the first author will be the one writing the paper, followed by the working group participants. The last

authorship positions will be given based on the number of samples included in the analysis, although in specific cases, this position might be filled based on other considerations.

- In the projects initiated by individual sites using data or samples of the other sites, the principle will be that the proposing site takes first and last author position. The number of authors included per site will be decided on on a per-paper basis. The IMpACT PIs will send a list of (2-5) potential co-authors to the first author upon request accompanied by information on what their role was in this paper. A decision will be made going from there.
- Each site will prepare a standard list of acknowledgements (people and funding agencies), that will be placed in all papers. Please send this list to Barbara, who will compile it for all sites and send it out to everybody.
- We will use a two-week rule, which means that co-authors that do not react within 2 weeks upon a (once-repeated) request for information or comments or a signature etc, will be removed from the author list. The PI of the site of such an author will be notified if this is threatening to happen.

### **3. Database of phenotypes and genotypes**

At this moment the data have to be compiled by every site and sent to another that has to take the effort to put all data together, which are often in slightly different formats. All of us agree that a database will save us time and prevent mistakes. We have to make sure, though, that the informed consent given by our study participants allows establishment of such a database.

- We would like to establish a centralized database of phenotypes and genotypes
- Somebody has to be appointed to make this database, get all data from the sites, clean the dataset and periodically update the database
- We will make freezes of the data and name these freezes, so we can refer to them in the papers.
- 'Dropbox' might be a website format that we can use to give us privacy for the database and ensure access only to the participating sites.
- The database might use the linkage format that we already have, and add all relevant phenotypic and genotypic data to it. In addition, information on DNA source should be added.
- We might be able to get some funding for the database from the European Brain Foundation.
- The database issue will be discussed further during a next IMpACT meeting.

Another issue is that we need to include the instruments and description of the new active IMpACT sites into the same format that we have used for the existing ones. Barbara will send the template to Phil and Eric/Steve.

We also have to think of ways how to best harmonize the phenotype data from the different groups/instruments.

#### 4. Possibilities for funding, where and how?

- IMpACT has participated in a number of (pre-)proposals to the EU as of December 2008 (the DADA project on ADHD and substance abuse and the PsySys project from the IoP), but the chances for getting funding via these projects is generally low.
- We require additional funding for several aims: 1) GWAS of the existing samples (which is now 2900 patient and 3500 control samples); 2) prospective study using a common protocol for evaluation of participants.
  - For 1) we have been offered to come talk to Eli Lilly during the Network meeting. We think, though, that it would be better to ask several industries to contribute funding, as o minimize potential bias. Another possibility to get funding for a GWAS would be via CIDR. Barbara together with Steve will look into the requirements for this.
  - For 2) one of the most important issues is to get to a common protocol. For this, we will have to continue our discussions, via e-mail and phone calls to decide whether the existing proposal (see below) is good or should be changed. An issue is the fact that the would have to pay for the CAADID, which we might change into a translated version of the DIVA, which Barbara will distribute.

#### A minimal protocol for adult ADHD phenotyping for genetic studies

- **Clinical interview**, e.g. the CAADID
- **ADHD-rating scale to assess severity of symptoms**, e.g. ADHD-RS or CAARS
- **Interview to assess comorbidity**, the SCID-I and –II
- **Personality questionnaire**, e.g. the NEO-P or the Zuckerman personality questionnaire

#### 5. Logo for IMpACT

Not discussed due to time constraints

#### 6. IMPACT, IMpACT, impACT

*Remark Barbara: Although this issue was also not discussed due to time constraints, I spoke to most of you who let me know that they agreed with using IMpACT as the way to depict the name of our group. I therefore have the feeling that we have a decision regarding this point. If you are strongly opposed to this, please let me know.*

### Things to do:

	<b>Required action</b>	<b>Person/group required to take action</b>	<b>Entry date into list</b>	<b>Deadline</b>
1	Send BDNF draft to IMpACT co-authors	Spain	6-12-08	asap
2	Send 5-HTT draft to IMpACT co-authors	Norway	6-12-08	January 2009
3	Send phenotype information to Germany	Norway, Spain	6-12-08	Asap
4	Send samples of patients and controls to Spain	Phil	6-12-08	15-1-2009
5	Prepare a standard list of acknowledgements (people and funding agencies) and send to Barbara	All sites	6-12-08	Asap
6	Check if the informed consent given by our study participants allows establishment of such a database. Send info to Barbara	All sites	6-12-08	Asap
7	Find out if somebody at your site is willing to set up and take care of the database	All sites	6-12-08	Before next meeting
8	Add information on numbers, instruments and procedures to description as in the DAT1 meta-analysis paper, send to Barbara	Phil Eric, Steve	6-12-08	asap
9	Look into possibilities for GWAS funding via CIDR	Barbara Steve	6-12-08	asap
10	Send DIVA (English version) to IMpACT members	Barbara	6-12-08	asap
11	Propose LOGO for IMpACT	All sites	6-12-08	asap
12	Start discussion about phenotyping protocol	All sites	6-12-08	asap
13	Plan new meeting in March or April	Barbara	6-12-08	asap